These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
115 related articles for article (PubMed ID: 17851243)
1. Hepatitis C treatment of opioid dependants receiving maintenance treatment: results of a Norwegian pilot study. Krook AL; Stokka D; Heger B; Nygaard E Eur Addict Res; 2007; 13(4):216-21. PubMed ID: 17851243 [TBL] [Abstract][Full Text] [Related]
2. [Quality assurance in patient addiction treated with drug substitution]. Krankenpfl J; 2005; 43(7-10):248. PubMed ID: 16515317 [No Abstract] [Full Text] [Related]
3. [Treatment of chronic hepatitis C within a heroine-assisted treatment program]. Deibler P; Haasen C; Reimer J Dtsch Med Wochenschr; 2006 Dec; 131(50):2835-7. PubMed ID: 17160765 [TBL] [Abstract][Full Text] [Related]
4. Treatment for hepatitis C virus infection among people who inject drugs attending opioid substitution treatment and community health clinics: the ETHOS Study. Grebely J; Alavi M; Micallef M; Dunlop AJ; Balcomb AC; Phung N; Weltman MD; Day CA; Treloar C; Bath N; Haber PS; Dore GJ; Addiction; 2016 Feb; 111(2):311-9. PubMed ID: 26451534 [TBL] [Abstract][Full Text] [Related]
5. Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin. Bronowicki JP; Ouzan D; Asselah T; Desmorat H; Zarski JP; Foucher J; Bourlière M; Renou C; Tran A; Melin P; Hézode C; Chevalier M; Bouvier-Alias M; Chevaliez S; Montestruc F; Lonjon-Domanec I; Pawlotsky JM Gastroenterology; 2006 Oct; 131(4):1040-8. PubMed ID: 17030174 [TBL] [Abstract][Full Text] [Related]
6. Hazardous alcohol consumption and other barriers to antiviral treatment among hepatitis C positive people receiving opioid maintenance treatment. Watson B; Conigrave KM; Wallace C; Whitfield JB; Wurst F; Haber PS Drug Alcohol Rev; 2007 May; 26(3):231-9. PubMed ID: 17454012 [TBL] [Abstract][Full Text] [Related]
7. Hepatitis C treatment in patients with drug addiction: clinical management of interferon-alpha-associated psychiatric side effects. Schaefer M; Mauss S Curr Drug Abuse Rev; 2008 Jun; 1(2):177-87. PubMed ID: 19630716 [TBL] [Abstract][Full Text] [Related]
8. Relapse to opioid use after treatment of chronic hepatitis C with pegylated interferon and ribavirin. Matthews AM; Fireman M; Zucker B; Sobel M; Hauser P Am J Psychiatry; 2006 Aug; 163(8):1342-7; quiz 1479. PubMed ID: 16877644 [No Abstract] [Full Text] [Related]
9. Rationale and design of a randomized controlled trial of directly observed hepatitis C treatment delivered in methadone clinics. Litwin AH; Berg KM; Li X; Hidalgo J; Arnsten JH BMC Infect Dis; 2011 Nov; 11():315. PubMed ID: 22078241 [TBL] [Abstract][Full Text] [Related]
10. Hepatitis C treatment in "difficult-to-treat" psychiatric patients with pegylated interferon-alpha and ribavirin: response and psychiatric side effects. Schaefer M; Hinzpeter A; Mohmand A; Janssen G; Pich M; Schwaiger M; Sarkar R; Friebe A; Heinz A; Kluschke M; Ziemer M; Gutsche J; Weich V; Halangk J; Berg T Hepatology; 2007 Oct; 46(4):991-8. PubMed ID: 17668880 [TBL] [Abstract][Full Text] [Related]
11. A prospective controlled study of interferon-based therapy of chronic hepatitis C in patients on methadone maintenance. Mauss S; Berger F; Goelz J; Jacob B; Schmutz G Hepatology; 2004 Jul; 40(1):120-4. PubMed ID: 15239094 [TBL] [Abstract][Full Text] [Related]
12. Effects of pegylated interferon alfa-2b on the pharmacokinetic and pharmacodynamic properties of methadone: a prospective, nonrandomized, crossover study in patients coinfected with hepatitis C and HIV receiving methadone maintenance treatment. Berk SI; Litwin AH; Arnsten JH; Du E; Soloway I; Gourevitch MN Clin Ther; 2007 Jan; 29(1):131-8. PubMed ID: 17379053 [TBL] [Abstract][Full Text] [Related]
14. [Peginterferon alfa-2a plus ribavirin for initial treatment of chronic hepatitis C in Korea]. Lee H; Choi MS; Paik SW; Kim JH; Kim DY; Lee JH; Koh KC; Yoo BC; Rhee JC; Song SM Korean J Hepatol; 2006 Mar; 12(1):31-40. PubMed ID: 16565604 [TBL] [Abstract][Full Text] [Related]
15. Successful treatment of chronic hepatitis C with pegylated interferon in combination with ribavirin in a methadone maintenance treatment program. Litwin AH; Harris KA; Nahvi S; Zamor PJ; Soloway IJ; Tenore PL; Kaswan D; Gourevitch MN; Arnsten JH J Subst Abuse Treat; 2009 Jul; 37(1):32-40. PubMed ID: 19038524 [TBL] [Abstract][Full Text] [Related]
16. Adherence to hepatitis C treatment in recovering heroin users maintained on methadone. Sylvestre DL; Clements BJ Eur J Gastroenterol Hepatol; 2007 Sep; 19(9):741-7. PubMed ID: 17700258 [TBL] [Abstract][Full Text] [Related]
17. Premature treatment discontinuation in HIV/HCV-coinfected patients receiving pegylated interferon plus weight-based ribavirin. Soriano V; Miralles C; Berdún MA; Losada E; Aguirrebengoa K; Ocampo A; Arazo P; Cervantes M; de los Santos I; San Joaquín I; Echeverria S; Galindo MJ; Asensi V; Barreiro P; Sola J; Hernandez-Burruezo JJ; Guardiola J; Blanco F; Martin-Carbonero L; García-Samaniego J; Nuñez M; Antivir Ther; 2007; 12(4):469-76. PubMed ID: 17668555 [TBL] [Abstract][Full Text] [Related]
18. Interferon alpha-2a plus ribavirin 1,000/1,200 mg versus interferon alpha-2a plus ribavirin 600 mg for chronic hepatitis C infection in patients on opiate maintenance treatment: an open-label randomized multicenter trial. Huber M; Weber R; Oppliger R; Vernazza P; Schmid P; Schönbucher P; Bertisch B; Meili D; Renner EL Infection; 2005 Feb; 33(1):25-9. PubMed ID: 15750756 [TBL] [Abstract][Full Text] [Related]
19. [Buprenorphine and methadone to opiate addicts--a randomized trial]. Kristensen Ø; Espegren O; Asland R; Jakobsen E; Lie Ø; Seiler S Tidsskr Nor Laegeforen; 2005 Jan; 125(2):148-51. PubMed ID: 15665884 [TBL] [Abstract][Full Text] [Related]
20. Treatment with peg-interferon alfa-2b and ribavirin of hepatitis C virus-associated mixed cryoglobulinemia: a pilot study. Mazzaro C; Zorat F; Caizzi M; Donada C; Di Gennaro G; Maso LD; Carniello G; Virgolini L; Tirelli U; Pozzato G J Hepatol; 2005 May; 42(5):632-8. PubMed ID: 15826710 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]